1st Edition

Cancer Targeting Therapies Conventional and Advanced Perspectives

Edited By Muhammad Yasir Ali, Shazia Bukhari Copyright 2024
312 Pages 35 Color & 2 B/W Illustrations
by CRC Press

312 Pages 35 Color & 2 B/W Illustrations
by CRC Press

312 Pages 35 Color & 2 B/W Illustrations
by CRC Press

This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and... Read more
    1. History of Cancer Therapies
    2. Isma Iqbal, Daulat Haleem Khan, Maria Manan, Zainab Abdullah, , Muhammad Ali Syed, Sana Hanif, Zeliha Selamoglu, Muhammad Yasir Ali, Azhar Rasul

    3. Cancer and Carcinogens
    4. Saba Riaz, Azhar Rasul, Muhammad Asif Khalil, Laiba Ameen, Komal Riaz, Samreen Gul Khan, Sevki Adem, Mudassir Hassan, Muhammad Javid Iqbal, Muhammad Asrar, Muhammad Yasir Ali

    5. Causes of Death from Cancer
    6. Hafiz Muhammad Irfan, Muhammad Ihtisham Umar, Usman Sabir, Muhammad Yasir Ali, Ummaima Shahzad

    7. Passive Targeting
    8. Malik Saadullah, Amna Sehar, Khurram Afzal, Ijaz Ali, Shams ul Hassan, Muhammad Yasir Ali

    9. Cancer Active Targeting Strategies
    10. Tanzeela Awan, Ghazala Ambreen, Uzma Saher, Saira Afzal, Muhammad Yasir Ali, Asia Naz Awan

      Conventional Cancer Therapies

    11. Oral Anticancer Therapies
    12. Ayesha Saeed, Liaqat Hussain, Hua Narenmandura, Qian Qian Wang, Muhammad Yasir Ali, Ummaima Shahzad, Ijaz Ali

    13. Parenteral Anticancer Therapies
    14. Mishal Fatima, Liaqat Hussain, Yasen Maimaitiyiming, Hua Naranmandura, Ayesha Saeed, Yang Chang, Muhammad Yasir Ali, Ummaima Shahzad

      Advanced Cancer Therapies

    15. The Advent of Micro and Nano-spheres for Cancer Treatment
    16. Asia Naz Awan, Rabia Iqtadar, Sabahat Abdullah, Muhammad Yasir Ali, Imran Tariq

    17. The Emergence of Liposomes in Cancer Therapy
    18. Asia Naz Awan, Sabahat Abdullah, Ayesha Naseer, Muhammad Yasir Ali, Daulat Haleem Khan

    19. Niosomes-Based Anticancer Therapies
    20. Daulat Haleem Khan, Muhammad Yasir Ali, Muhammad Asim Farooq, Muhammad Ali Syed, Azhar Rasul, Shazia Anwar Bukhari, Sevki Adem, Maria Manan

    21. Solid Lipid Nanoparticles-Based Anticancer Therapies
    22. Mulazim Hussain Asim, Muhammad Yasir Ali, Shumaila Arshad, Ummaima Shahzad, Arshad Mahmood, Syed Atif Raza, Alia Erum, Ali Moghadam

    23. Mesoporous Nanoparticles-Based Anticancer Therapies
    24. Tanzeela Awan, Uzma Saher, Muhammad Yasir Ali Umair Amin, Sajid Ali

    25. Antibody-Based Cancer Therapies
    26. Malik Saadullah, Hafsa Tariq, Muhammad Yasir Ali, Saeed Ahmad, Nisar ur Rehman

    27. Aptamer-Based Anticancer Therapies
    28. Muhammad Yasir Ali, Ummaima Shahzad, Maryam Shabir, Nisar ur Rehman, Saeed Ahmad, Udo Bakowsky, Umair Amin, Imran Tariq, Ghazala Ambreen

    29. Polyamidoamines-Based Anticancer Therapies
    30. Maria Manan, Rida Siddique, Maryam Shabir, Azhar Rasul, Nosheen Aslam, Uzma Saleem, Muhammad Yasir Ali, Shazia Anwer Bukhari, Mulazim Hussain Asim

    31. Photodynamic Therapies for Cancer Treatment

Ayesha Sadiqa, Saba Riaz, Azhar Rasul, Rabia Zara, Khudeja Afroz, Zunaira Saeed, Gul Bushra Khan, Khatereh Khorsandi, Muhammad Yasir Ali

Biography

Dr. Muhammad Yasir Ali

My pharmacy career started back in 2002 as a graduate student, leading to the achievement of a graduate and then a master's degree in Pharmaceutical Technology in 2009. Nevertheless, with my thirst for knowledge as a student and researcher, an in-line experience in production and quality control in Roche Pakistan helped me in knowing the ropes of the subject.

Later on, I joined the university of Lahore as a faculty member and taught different courses to pharmacy graduates, especially pharmaceutical technology. In 2011 after joining my current job, I kept on teaching and indulged myself in research which is still going on, meanwhile, I got my doctorate (Pharmaceutical Technology) from Germany.

I have more than 30 research publications, one research project, practical application of pharmacy knowledge in the form of different marketed products, several book chapters, and one book as editor in my research basket. I got chances of presenting research papers and scientific lectures in different organizations in Germany, USA, UK, and Pakistan.

Dr. Shazia Bukhari

I completed my undergraduate studies from the Bahuddin Zakariya University, Multan (1998-2001) and my M.Phil. studies from the Department of Biochemistry, University of Agriculture, Faisalabad Pakistan (2001-2003). Then I continued higher studies in Punjab University and earned Ph.D. degree in Biochemistry (2005-2009).

I started my career at Hi-Tech Lab, University of Agriculture, Faisalabad (2003 – 2004). Then I joined Center for Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad as Research Officer/Lecturer (2004-2011). Then I joined Government College University as Assistant Professor (2011-2014). I was promoted to Associate Professor (2014-2019 and Professor (2019 to date) in the Department of Biochemistry of the same university.

My research interest focuses on the exploration of indigenous flora for treatment of various diseases, based on an understanding of the mechanisms underlying the successful interactions between the plant components and disease. For this purpose, we are now using computational tools to correlate the laboratory findings with computer modeling. I am also working to enhance resistance of wheat (Triticum aestivum) against fungus diseases like rust. For this purpose, we have been transforming rust resistance and Pathogenesis-Related genes, isolated from local verities, and transform into high yielding wheat commercial varieties. I have screened and characterized nine novel genes relating rust resistance and pathogenesis related and deposited in gene bank. I am currently running two projects for achieving this goal approved by HEC: 3.679,655 million) as PI and 2nd approved by Technology Development Funds. HEC (13.609 million) as PI.